ANAPTYSBIO, INC — Director's Dealing 2018

Dec 13, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2018-12-10

Reporting Person: Suria Hamza (Director, President, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-10	Common Stock	M	30587	$1.12	Acquired	65649	Direct
2018-12-10	Common Stock	S	15276	$70.5736	Disposed	50373	Direct
2018-12-10	Common Stock	S	10347	$71.4894	Disposed	40026	Direct
2018-12-10	Common Stock	S	4964	$72.4829	Disposed	35062	Direct
2018-12-11	Common Stock	S	4998	$70.83	Disposed	30064	Direct
2018-12-12	Common Stock	M	30000	$1.12	Acquired	60064	Direct
2018-12-12	Common Stock	S	12003	$71.1056	Disposed	48061	Direct
2018-12-12	Common Stock	S	9673	$71.9237	Disposed	38388	Direct
2018-12-12	Common Stock	S	8324	$72.8758	Disposed	30064	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-10	Employee Stock Option (Right to Buy)	$1.12	M	30587	Disposed	2021-12-08	Common Stock (30587)	Direct
2018-12-12	Employee Stock Option	$1.12	M	30000	Disposed	2021-12-08	Common Stock (30000)	Direct

Footnotes

F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.01 to $71.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.01 to $71.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.13 to $73.07 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.51 to $71.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.51 to $72.48 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.52 to $73.04 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The stock option is fully vested and immediately exercisable.

F9: In addition to the remaining options to purchase 80,361 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 796,205 shares of common stock, which options vest according to their terms, and (ii) 30,064 shares of common stock held directly.